These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 10215361)
21. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. Prasher VP Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527 [TBL] [Abstract][Full Text] [Related]
22. Rivastigmine in the treatment of alcohol-induced persisting dementia. Gibson RC; Barnaby L West Indian Med J; 2003 Mar; 52(1):59-61. PubMed ID: 12806761 [TBL] [Abstract][Full Text] [Related]
28. [Mechanisms of action of Alzheimer medications]. Alhainen K Duodecim; 2003; 119(20):1959-66. PubMed ID: 14640001 [No Abstract] [Full Text] [Related]
29. Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors. Bianchetti A; Rozzini R; Trabucchi M Curr Med Res Opin; 2003; 19(4):350-3. PubMed ID: 12841930 [TBL] [Abstract][Full Text] [Related]
30. Drug treatment of Alzheimer's disease and responders to rivastigmine beyond 12 weeks. McMillan H Int J Geriatr Psychiatry; 1999 Dec; 14(12):1078-9. PubMed ID: 10607978 [No Abstract] [Full Text] [Related]
31. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine. Linkins KW; Lloyd JR; Hjelmstad GO; Strausbaugh HJ Pharmacoeconomics; 2000 Dec; 18(6):609-12. PubMed ID: 11227398 [No Abstract] [Full Text] [Related]
32. Drug treatment for Alzheimer's disease. Freyne A; Cooney C Ir Med J; 1999; 92(7):424-5. PubMed ID: 10967863 [No Abstract] [Full Text] [Related]
33. Featured CME topic: dementia. Medication update. Slagle MA South Med J; 2001 Jul; 94(7):678-81. PubMed ID: 11531174 [No Abstract] [Full Text] [Related]
34. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy]. Richard E; Walstra GJ; van Campen J; Vissers E; van Gool WA Ned Tijdschr Geneeskd; 2002 Jan; 146(1):24-7. PubMed ID: 11802333 [TBL] [Abstract][Full Text] [Related]
35. [Rivastigmine in current clinical practice in patients with mild to moderate Alzheimer's disease]. Dartigues JF; Goulley F; Bourdeix I; Péré JJ; Barberger-Gateau P Rev Neurol (Paris); 2002 Sep; 158(8-9):807-12. PubMed ID: 12386525 [TBL] [Abstract][Full Text] [Related]
37. Adherence to cholinesterase inhibitors in patients with Alzheimer's disease. Blais L; Kettani FZ; Perreault S; Leroux JC; Forget A; Kergoat MJ J Am Geriatr Soc; 2009 Feb; 57(2):366-8. PubMed ID: 19207161 [No Abstract] [Full Text] [Related]
38. Rivastigmine in patients with Alzheimer's disease and concurrent hypertension. Erkinjuntti T; Skoog I; Lane R; Andrews C Int J Clin Pract; 2002 Dec; 56(10):791-6. PubMed ID: 12510954 [TBL] [Abstract][Full Text] [Related]
39. Do cholinesterase inhibitors slow progression of Alzheimer's disease? Farlow MR Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366 [TBL] [Abstract][Full Text] [Related]
40. Medical treatment of Alzheimer's disease: past, present, and future. Ott BR Med Health R I; 2002 Jul; 85(7):210-2. PubMed ID: 12182092 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]